Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry.
Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry (RAD Winter 2023)
Challenge
This is a RAD Winter 2023 presentation of the same therapeutic inertia PRO study as Row 22 (Fall Clinical 2024). Earlier version of the analysis with the same core finding — a significant proportion of patients fail to achieve PRO targets with systemic therapy over 12 months without treatment escalation.
Solution
TARGET-DERM AD registry used to track PRO trajectories in patients not meeting AHEAD targets at 3–12 months post-systemic therapy initiation, quantifying the patient-reported burden of therapeutic inertia.
Impact
Multi-venue dissemination of the therapeutic inertia PRO findings broadens the evidence base for prescriber education and treatment escalation advocacy across key AD scientific communities.
